The stock of Harvard Bioscience Inc (HBIO) has seen a 4.49% increase in the past week, with a 36.54% gain in the past month, and a -16.59% decrease in the past quarter. The volatility ratio for the week is 13.48%, and the volatility levels for the past 30 days are at 27.54% for HBIO. The simple moving average for the past 20 days is 1.68% for HBIO’s stock, with a -65.22% simple moving average for the past 200 days.
Is It Worth Investing in Harvard Bioscience Inc (NASDAQ: HBIO) Right Now?
Additionally, the 36-month beta value for HBIO is 1.56. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for HBIO is 37.41M and currently, short sellers hold a 7.57% ratio of that float. The average trading volume of HBIO on June 26, 2025 was 11.79M shares.
HBIO) stock’s latest price update
Harvard Bioscience Inc (NASDAQ: HBIO) has experienced a rise in its stock price by 3.18 compared to its previous closing price of 0.49. However, the company has seen a gain of 4.49% in its stock price over the last five trading days. globenewswire.com reported 2025-06-02 that HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors.
Analysts’ Opinion of HBIO
The Benchmark Company, on the other hand, stated in their research note that they expect to see HBIO reach a price target of $4, previously predicting the price at $3. The rating they have provided for HBIO stocks is “Buy” according to the report published on March 10th, 2023.
HBIO Trading at 23.97% from the 50-Day Moving Average
After a stumble in the market that brought HBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.84% of loss for the given period.
Stock Fundamentals for HBIO
Current profitability levels for the company are sitting at:
- -0.48 for the present operating margin
- 0.56 for the gross margin
The net margin for Harvard Bioscience Inc stands at -0.64. The total capital return value is set at -1.81. Equity return is now at value -138.80, with -54.52 for asset returns.
Based on Harvard Bioscience Inc (HBIO), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at 0.42. The debt to equity ratio resting at 0.49. The interest coverage ratio of the stock is -26.43.
Currently, EBITDA for the company is -1.47 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 0.26. The receivables turnover for the company is 6.78for trailing twelve months and the total asset turnover is 1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.81.
Conclusion
In conclusion, Harvard Bioscience Inc (HBIO) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
